Strata Critical Medical (SRTA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
28 May, 2026Opening remarks and agenda
Meeting opened by outgoing lead independent director, with recognition of departing directors and introduction of new board leadership.
Virtual meeting format explained, with procedures for stockholder questions and rules of conduct outlined.
Introduction of directors, executive officers, and representatives from Deloitte & Touche LLP and Broadridge Financial Solutions.
Board and executive committee updates
Transition in board leadership with the retirement of two directors and nomination of a new lead independent director.
Board composition and roles of executive officers clarified for attendees.
Shareholder proposals
Election of two class 2 directors to serve until the 2029 annual meeting, with board recommendation to vote in favor.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending 31 December 2026.
Advisory vote on executive compensation (say on pay), held annually per prior stockholder guidance.
Latest events from Strata Critical Medical
- Integrated transplant logistics leader leverages tech, regulatory shifts, and M&A for rapid growth.SRTA
16th Annual East Coast IDEAS Conference11 Jun 2026 - Strong Q1 2026 growth and industry leadership position support continued expansion and profitability.SRTA
Investor presentation8 May 2026 - Revenue up 87% to $67.4M, net income positive, and guidance reaffirmed for 2026.SRTA
Q1 20266 May 2026 - Asset-light, agnostic transplant logistics platform drives rapid growth and national expansion.SRTA
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.SRTA
Proxy filing14 Apr 2026 - Proxy covers director elections, auditor ratification, and executive pay amid a strategic business shift.SRTA
Proxy filing14 Apr 2026 - Q4 2025 revenue soared 83.5% YoY, with 2026 guidance raised on strong growth and integration.SRTA
Q4 20253 Mar 2026 - Q2 2024 delivered 11.4% revenue growth, positive Adjusted EBITDA, and record Medical results.SRTA
Q2 20242 Feb 2026 - Q3 revenue up 5% to $74.9M, Medical leads growth, margins and liquidity strong, outlook positive.SRTA
Q3 202414 Jan 2026